Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public
This article was originally published in RPM Report
Executive Summary
FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare?
You may also be interested in...
Complete Transparency: Recent FDA Decisions Renew Calls For Making Complete Response Letters Public
Three major stakeholders in drug development—regulators, industry, and investors—say they want or could live with FDA complete response letters being made public. Why aren’t they, and will it happen in the current political environment?
FDA Releases Report on Transparency to Regulated Industry: Not Much To See Here
The third phase of the Food & Drug Administration’s Transparency Initiative lists 19 ways that the agency plans to improve transparency to the industries it regulates. FDA is also seeking comments on five proposed steps. Unlike earlier phases, there isn’t too much to see here.
Complete Transparency: Recent FDA Decisions Renew Calls For Making Complete Response Letters Public
Three major stakeholders in drug development—regulators, industry, and investors—say they want or could live with FDA complete response letters being made public. Why aren’t they, and will it happen in the current political environment?